Inhalation and Nasal Spray is a kind of drug used to relieve sneezing, runny, stuffy, or itchy nose and itchy, watery eyes caused by hay fever or other allergies.
This report contains market size and forecasts of Inhalation and Nasal Spray Generic Drugs in global, including the following market information:
- Global Inhalation and Nasal Spray Generic Drugs Market Revenue, 2017-2022, 2023-2028, ($ millions)
- Global Inhalation and Nasal Spray Generic Drugs Market Sales, 2017-2022, 2023-2028, (K Units)
Global top five Inhalation and Nasal Spray Generic Drugs companies in 2021 (%)
The global Inhalation and Nasal Spray Generic Drugs market was valued at 9067.6 million in 2021 and is projected to reach US$ 13660 million by 2028, at a CAGR of 6.0% during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Corticosteroids Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Inhalation and Nasal Spray Generic Drugs include Teva, Sandoz (Novartis), Mylan, Allergan, Cipla, Akorn, Apotex, Sun Pharma (Ranbaxy) and Nephron Pharma, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Inhalation and Nasal Spray Generic Drugs manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Inhalation and Nasal Spray Generic Drugs Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Inhalation and Nasal Spray Generic Drugs Market Segment Percentages, by Type, 2021 (%)
- Corticosteroids
- Bronchodilators
- Combinations
- Decongestant Sprays
- Others
Global Inhalation and Nasal Spray Generic Drugs Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Inhalation and Nasal Spray Generic Drugs Market Segment Percentages, by Application, 2021 (%)
- Asthma
- COPD
- Allergic Rhinitis
- Others
Global Inhalation and Nasal Spray Generic Drugs Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Inhalation and Nasal Spray Generic Drugs Market Segment Percentages, By Region and Country, 2021 (%)
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- France
- U.K.
- Italy
- Russia
- Nordic Countries
- Benelux
- Rest of Europe
- Asia
- China
- Japan
- South Korea
- Southeast Asia
- India
- Rest of Asia
- South America
- Brazil
- Argentina
- Rest of South America
- Middle East & Africa
- Turkey
- Israel
- Saudi Arabia
- UAE
- Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
- Key companies Inhalation and Nasal Spray Generic Drugs revenues in global market, 2017-2022 (Estimated), ($ millions)
- Key companies Inhalation and Nasal Spray Generic Drugs revenues share in global market, 2021 (%)
- Key companies Inhalation and Nasal Spray Generic Drugs sales in global market, 2017-2022 (Estimated), (K Units)
- Key companies Inhalation and Nasal Spray Generic Drugs sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
- Teva
- Sandoz (Novartis)
- Mylan
- Allergan
- Cipla
- Akorn
- Apotex
- Sun Pharma (Ranbaxy)
- Nephron Pharma
- Beximco Pharma
- Hikma (Roxane)
- XIANJU PHARMA
